29 August 2000 22:40 [Source: ICIS news]
HOUSTON (CNI)--Access Pharmaceuticals said Tuesday it had agreed to license its OraRinse, amlexanox cream and amlexanox gel to Spain's Laboratorios Dr Esteve SA and its affiliate Isdin SA.
Under terms of the agreement, Esteve and Isdin will make up front licensing payments and milestone payments. Dallas, Texas-based Access will receive a percentage of product sales for supplying the product.
Said Kerry Gray, president and chief executive officer of Access: "This represents a continuation of our strategy to out-license product candidates to regional marketing partners who can effectively promote products to niche market sectors to maximise Access product revenues.
Access' OraRinse is for the prevention and treatment of mucositis in patients undergoing radiation and chemotherapy. Amlexanox 5% paste is for the treatment of canker sores.
Access is an emerging pharmaceutical company focused on developing both novel, low development risk product candidate sand technologies with longer-term major product opportunities.
Esteve, the third largest pharmaceutical company in Spain, will also make an equity investment in Access, and provide funding for European clinical research.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|